The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway. ##STR00001##

A lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. The lubricating oil base stock has a high temperature high shear (HTHS) viscosity of less than about 1.7 cP as determined by ASTM D4683, and a Noack volatility from about 15 to about 90 percent as determined by ASTM D5800. A lubricating oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. A method for improving one or more of thermal and oxidative stability, solubility and dispersancy of polar additives, deposit control and traction control in a lubricating oil by using as the lubricating oil a formulated oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein.

A lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. The lubricating oil base stock has a high temperature high shear (HTHS) viscosity of less than about 1.7 cP as determined by ASTM D4683, and a Noack volatility from about 15 to about 90 percent as determined by ASTM D5800. A lubricating oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. A method for improving one or more of thermal and oxidative stability, solubility and dispersancy of polar additives, deposit control and traction control in a lubricating oil by using as the lubricating oil a formulated oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein R.sup.1 is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.